Professor John Strang
Professor of Addictions & Head of Department
We are very proud to congratulate long-standing SSA Trustee, Professor Sir John Strang, who was named in HM Queen Elizabeth’s birthday honours list, 2016.
Professor Sir John Strang is one of only six addictions researchers outside North America identified by ISI (the Institute for Scientific Analysis) as a “Highly Cited Author” with a rate of citation in the “top one half of one percent of all publishing researchers in the last two decades”. He has published extensively in the addictions field, with more than 500 publications, and is Head of the Addictions Department. He also has extensive experience as a Lead Clinician for a wide range of treatments in community and residential settings and has been a Consultant Psychiatrist in addictions treatment for over 30 years.
Professor Strang is Head of the Addictions Department and is also Leader of the Addictions CAG (Clinical Academic Group) within King’s Health Partners, in which Addictions is one of the core areas of the Academic Health Science Centre (AHSC). This brings together university partners King’s College London (KCL) with the NHS from South London and Maudsley NHS Foundation Trust, King’s College Hospital, and Guy’s and St Thomas’s NHS Foundation Trust.
The Addictions Department itself is hugely productive. The highly influential report by RAND Europe rates Substance Abuse Research at the National Addiction Centre as leading the field in UK Universities, with our Addictions (Substance Abuse) publications leading the field at 13%, with all other institutions except two scoring under 5%.
Professor Strang has chaired and/or served on key committees or guidelines groups for the Department of Health, for NICE (the National Institute of Health and Clinical Excellence) and for the World Health Organisation (WHO). This provides opportunity to bring relevant evidence from new scientific studies and systematic reviews to the policy-making work of these committees.
Co-Authors
John Strang1, Ulrike Lorch2, Rebecca McDonald1, Jo Woodward3, Björn Bosse4, Helen Johnson3, Gill Mundin3, & Kevin Smith3 1 National Addiction Centre, King’s College London, London, UK; 2 Richmond Pharmacology Ltd, Croydon University Hospital, Croydon, UK; 3 Mundipharma Research Limited, Cambridge, UK; 4 Mundipharma Research GmbH & Co. KG, Limburg, Germany
Conflicts of interest:
John Strang and Rebecca McDonald are employed by the university King’s College London (KCL), UK. JS is a researcher and clinician who has worked with a range of governmental and non-governmental organisations, and with pharmaceutical companies to seek to identify new or improved treatments (including naloxone products), and from whom he and his employer (KCL) have received research funding, honoraria, travel costs and/or consultancy payments, including from Mundipharma to KCL for JS’ time and input to the study reported above. JS has also been named as an inventor in an earlier patent application filed by Euro-Celtique S.A. (an Independent Associated Company of Mundipharma Research Limited) and entitled ‘Intranasal Pharmaceutical Dosage Forms comprising Naloxone’. For fuller account for JS, see http://www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. KCL (employer for both JS and RM) has separately registered intellectual property on a novel buccal naloxone formulation with which JS and RM are involved. JS is supported by the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and KCL.
